Navigation Links
Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM)
Date:10/12/2011

CAMBRIDGE, Mass., Oct. 12, 2011 /PRNewswire/ -- Good Start Genetics,™ Inc., an innovative molecular diagnostics company developing the new gold standard in carrier screening, today announced that it will present results from the technical validation study for its proprietary next-generation DNA sequencing platform at the Annual Meeting of the American Society for Reproductive Medicine (ASRM).  ASRM will be held from October 15-19, 2011 at the Orange County Convention Center in Orlando, Florida.  

(Photo: http://photos.prnewswire.com/prnh/20111012/NY84930LOGO )

Greg Porreca, Ph.D., a company founder and the Director of Technology, is scheduled to present the data on Tuesday, October 18th during the Procedures and Techniques – Laboratory oral discussion session that will be held from 4:00 to 6:00 p.m. The presentation (abstract #0201) is titled, "A Novel Next-Generation DNA Sequencing Test for Detection of Disease Mutations in Carrier and Affected Individuals."  

Good Start Genetics' next-generation sequencing (NGS) platform is a highly accurate, high-throughput platform that evaluates patient DNA samples and is expected to yield high detection rates regardless of ethnicity by detection of both common and novel disease-causing mutations associated with recessive genetic disorders.

Routine genetic carrier screening has traditionally employed targeted mutation analysis technologies for genotyping, which, due to cost considerations, are designed to detect only a small number of the most common disease-causing mutations that are prevalent in only specific populations.  The NGS platform developed by Good Start Genetics, however, allows for a more comprehensive determination of carrier status in routine clinical practice because it is not limited to a small targeted mutation set and, therefore, can achieve high clinical sensitivities regardless of ethnicity.  Because this platform is highly scalable, it overcomes the cost limitations of the older, first-generation Sanger technique, which although also highly accurate, has had very limited use in routine clinical practice.  

Good Start Genetics will soon be offering testing services to U.S. fertility clinics through its state-of-the-art CLIA approved lab for all genetic disorders recommended by the American Congress of Obstetricians and Gynecologists (ACOG), the American College of Medical Genetics (ACMG) and several national Jewish advocacy organizations.

The study abstracts are available online at www.asrm.org.

About Good Start Genetics

Good Start Genetics is setting the new gold standard for carrier screening in routine clinical practice by making testing for the most comprehensive set of known and novel disease-causing mutations accessible. After years of development and rigorous validation, Good Start Genetics has harnessed the power of next-generation sequencing and other best-in-class technologies to provide highly accurate, actionable, and affordable tests for all ACOG and ACMG recommended disorders. For these reasons, fertility specialists and their patients can have a high degree of confidence in their carrier screening results and no longer have to compromise accuracy for price.

These tests were developed and their performance characteristics determined by Good Start Genetics™. They have not been cleared or approved by the U.S. Food and Drug Administration. However, the laboratory is regulated under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical testing, and the tests have been analytically validated in accordance with CLIA standards.


'/>"/>
SOURCE Good Start Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hologic to Preside Over NASDAQ Opening Bell Ceremony Marking the Start of Breast Cancer Awareness Month
2. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Postherpetic Neuralgia
3. Mark Your Calendar - Open Enrollment for Medicare Prescription Drug and Health Plans Starts Earlier
4. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
5. Roche Starts Early Stage Clinical Trial in Down Syndrome
6. Prostate Cancer Awareness Month Starts in September
7. Start-Up Helps Pharma Stay on Facebook
8. meridianEMR® Customers Start Receiving Meaningful Use Incentive Payments
9. Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
10. Sanofi Pasteur Starts Shipping Influenza Vaccine for the 2011-2012 Season
11. JumpStart Ventures Invests in Cleveland-based SPR Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 Invivotek, LLC, a ... in vivo pharmacology contract research organization (CRO), ... to its newly expanded preclinical research facility in ... provides a cleaner, renewable energy source to reduce costs ... Completion of the Genesis Solar Farm follows Invivotek,s recent ...
(Date:3/24/2017)... March 24, 2017  Zymo Research Corp., ... Hamilton Robotics, Inc., who designs, manufactures and ... collaboration that teams Zymo Research,s DNA methylation ... DNA extraction products with Hamilton,s high-throughput automation ... methods for microbiomics and RNA isolation for ...
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
Breaking Medicine Technology:
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician Dr. Justin ... a prestigious award honoring the top influencers on RealSelf—the most trusted online destination ... doctors and clinics. , In 2016, more than 82 million people visited RealSelf ...
(Date:3/24/2017)... ... 24, 2017 , ... Mediaplanet today announces distribution of its ... obstacles facing infection prevention and offer strategies for the health care community to ... , The print component of “Fighting Infection” is distributed within the Friday, March ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... found at 9618 Huebner Road. The clinic is the group’s 7th location in San ... Dr. Ali Higgins, PT, will provide care from the clinic, which opened March 22, ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... (ONS) wanted to create a communications platform that positions them as the go-to ... and ONS reinvented their online publication as an always-on, always-fresh news, views and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ( ... patients for colonoscopy at the HyGIeaCare® Center that is to be located adjacent ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):